Adjuvant therapy efficacy of Chinese drugs pharmaceutics for COPD patients with respiratory failure: a meta-analysis

Abstract

We performed a meta-analysis to evaluate the efficacy and safety of Western medicine combined with Tanreqing for patients with chronic obstructive pulmonary disease (COPD) and respiratory failure. We comprehensively searched several online databases from the times of their inception to November 2018. The trial quality was assessed using the bias risk tool recommended by the Cochrane library. Relative risks (RRs) and their 95% confidence intervals (CIs) for binary outcomes and weighted mean differences (MDs) with 95% CIs for continuous data were calculated. A fixed effect model indicated that integrated Tanreqing group experienced higher overall treatment effectiveness (RR = 1.23, 95% CI: 1.17–1.30, P=0.000). Pooled results from random effects models indicated the oxygen partial pressure of the test group was significantly higher than that of the control groups (MD = 9.55, 95% CI: 4.57–14.52, P<0.000). The carbon dioxide pressure of the test group was significantly lower than that of the control groups (MD = –6.06, 95% CI: –8.19 to –3.93, P=0.000). The lung function score of the test group was significantly higher than that of the control group (MD = 7.87, 95% CI: 4.45–11.29). Sensitivity analysis indicated that the data were statistically robust. Clinical effects of Western medicine combined with Tanreqing used to treat combined COPD/respiratory failure were better than those afforded by Western medicine; no serious adverse reactions were noted. However, publication bias was evident, and further trials with larger sample sizes are required.

Retracted: Gastrodin relieves inflammation injury induced by lipopolysaccharides in MRC‐5 cells by up‐regulation of miR‐103

“…21 This study attempted to investigate the potential of gastrodin for COPD management. Thus, preventing COPD has become a promising method for COPD management and a small fraction of researches have focused on the beneficial effects of traditional Chinese herbal medicine on this disease.…”

“…Thus, preventing COPD has become a promising method for COPD management and a small fraction of researches have focused on the beneficial effects of traditional Chinese herbal medicine on this disease. 21 This study attempted to investigate the potential of gastrodin for COPD management. To this end, LPS was applied to treat MRC-5 cells to construct a cell model of COPD.…”

A Double-blind Randomized Controlled Trial on the Effects of Montelukast on the Serum Level of Inflammatory Factors in Patients with Chronic Obstructive Pulmonary Disease

“…IL-18 belongs to the immunoglobulin superfamily and is produced by mononuclear cells (17). This cytokine is involved in the onset and development of COPD, and its level is directly related to the severity of the acute exacerbation of COPD (AECOPD) (18). Imaoka et al showed that serum levels of IL-18 in COPD patients and smokers were significantly higher than nonsmokers (19).…”

“…Due to the role of montelukast in reducing IL-1β levels in previous studies (24), and the role of inflammasome and caspase-1 in the production of these two cytokines (IL-1β and IL-18) (25), montelukast probably uses a similar mechanism to reduce the level of IL-18. This may explain the partial inhibitory effect of montelukast on the development of smoke-induced inflammation by reducing some inflammatory cytokines, such as IL- 18.…”

Clinical efficacy and safety of Tanreqing injection combined with antibiotics versus antibiotics alone in the treatment of pulmonary infection patients after chemotherapy with lung cancer: A systematic review and meta‐analysis

“…The main bioactive components in TRQ injection are flavonoids, phenolic acid, and lignans from Scutellaria baicalensis Georgi, Lonicera japonica flos, and Fructus Forsythiae (Wang, Liao, et al, 2016; Wang, Peng, & Zou, 2016). Studies have shown that baicalin, chlorogenic acid and phillyrin have good anti‐inflammatory, antibacterial, and antiviral activities (Feng et al, 2018; Liu, Li, Wang, Lu, & Wang, 2019). Related meta‐analysis found that TRQ injection was effective and safe in the treatment of respiratory tract infections such as pulmonary infection in patients with tuberculosis (Xiong et al, 2018), community‐acquired pneumonia (Huang et al, 2019) and hematological tumor with pulmonary infection (Ai, Xiao, & Wang, 2015).…”